 MINNEAPOLIS--BUSINESS WIRE--DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences. Details of the companys participation are as follows: 33rd Annual Roth Conference Details: DiaMedica Therapeutics management will deliver a fireside chat and participate in 1-on-1 meetings Company confere 